Patients with TSC2 variations may benefit from mTOR inhibitors like everolimus, which have demonstrated a >50% reduction in seizure frequency in TSC-related epilepsy patients (Krueger et al., 2013). This evidence concerns the gene MTOR and tuberous sclerosis.